Inhibrx Biosciences, Inc.
Close on Oct 19, 2026
- Market cap
- $1.41B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 13, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | After market close | – | $-2.34 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | After market close | – | $-2.15 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 19, 2026 | After market close | – | $-2.11 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 14, 2025 | After market close | – | $-2.28 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 13, 2025 | After market close | $1.30M | $-1.85 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 14, 2025 | After market close | – | $-2.80 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 17, 2025 | After market close | $100.00K | $-3.09 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | After market close | – | $-2.84 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 13, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 28, 2024 | Before market open | – | – | – |
Press releases
Announcements Inhibrx Biosciences filed with the SEC
INHIBRX Investor Presentation Innovation Driven Outcomes Focused •
Regulation FD disclosure · EX-99.1 to Form 8-K
Inhibrx’s INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
P R OP R IE TAR Y AN D C ON FID E N TI A L; N OT FOR D IS TR IB U TION INBRX-106 Investor Overview September 2026
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Inhibrx Reports Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million
Material agreement · New financial obligation · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Inhibrx Reports First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
INHIBRX Investor Presentation Innovation Driven Outcomes Focused
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
INHIBRX Investor Presentation Innovation Driven Outcomes Focused
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
INHIBRX Investor Presentation Innovation Driven Outcomes Focused
Regulation FD disclosure · EX-99.1 to Form 8-K
Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Inhibrx Reports Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
INHIBRX Investor Presentation Innovation Driven Outcomes Focused
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Inhibrx Reports Second Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Inhibrx Reports First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Inhibrx Biosciences Announces Loan Agreement with Oxford Finance
Material agreement · New financial obligation · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Inhibrx Biosciences Reports Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Inhibrx Biosciences Reports Second Quarter 2024 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
INHIBRX Investor Presentation Innovation Driven Outcomes Focused
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
INHIBRX Investor Presentation Innovation Driven Outcomes Focused
Regulation FD disclosure · EX-99.1 to Form 8-K
11025 N. TORREY PINES ROAD, SUITE 140
Regulation FD disclosure · EX-99.1 to Form 8-K
Inhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Outcomes Focused Innovation Driven March 2023
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Inhibrx Announces Updated Efficacy and Safety Data from the Expansion Cohorts in the Phase 1 Trial of INBRX-109 for the Treatment of Chondrosarcoma
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Inhibrx Reports Third Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
11025 N. Torrey Pines Rd Ste 200 La Jolla, CA 92037 www.inhibrx.com
Material agreement · New financial obligation · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Inhibrx Announces Opportunity for Accelerated Approval Pathway on Functional AAT Serum Levels for INBRX-101 in AATD and Announces Bronchoalveolar Lavage Fluid Detection Results from the Phase 1 Study
Material agreement · New financial obligation · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
European Medicines Agency Grants Orphan Drug Designation to INBRX-109 for the Treatment of Chondrosarcoma
Other events · EX-99.1 to Form 8-K
11025 N. Torrey Pines Rd Ste 200 La Jolla, CA 92037 www.inhibrx.com
Regulation FD disclosure · EX-99.1 to Form 8-K
Inhibrx Reports Second Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Inhibrx Announces Completion of Phase 1 Combination Dose Escalation for INBRX-105, a Novel Targeted 4-1BB Agonist, and Draws an Additional $60 Million from Oxford Finance
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K